

## IAS 2019 Track categories

---

### Track A – Basic science

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

#### HIV evolution and phylodynamics (intra- and inter-host)

- A1 Viral origins, evolution and diversity
- A2 Viral fitness and resistance

#### Virology

- A3 Viral entry (attachment, receptors and co-receptors, penetration and tropism)
- A4 Viral replicative cycle (reverse transcription, integration, viral assembly and maturation)
- A5 Viral regulation (transcriptional and gene expression regulation)

#### Immune responses (innate and adaptive) during infection

- A6 Innate immunity
- A7 Humoral immunity (including broadly neutralizing antibodies)
- A8 Cellular immunity
- A9 Mucosal immunity

#### HIV/SIV pathogenesis (immune function and dysfunction)

- A10 Systemic immune activation and inflammation
- A11 T cell depletion and reconstitution, and immune ageing
- A12 Microbiomes and microbial translocation
- A13 Correlates of HIV susceptibility and disease progression (biomarkers and genetics)
- A14 Co-morbidities (HIV)

#### Neuropathogenesis

- A15 Virology of CNS compartment
- A16 Neuroimmunity
- A17 Neurodegeneration
- A18 Biomarkers and imaging

#### Latency and viral reservoirs

- A19 Viral mechanisms of HIV/SIV persistence and latency
- A20 Host cellular factors and latency
- A21 Cellular and tissue reservoirs of HIV/SIV
- A22 Characterizing HIV/SIV reservoirs and rebounding virus

#### Cure strategies

- A23 Eliminating and silencing latency

A24 Immunotherapy

A25 Vaccines

A26 Gene therapy

#### Natural protection against HIV and AIDS

A27 HIV-1 controllers (including post-treatment controllers) and long-term non-progressors

A28 Highly exposed seronegative individuals (HESN)

A29 Correlates of immune protection

#### Transmission and acute infection

A30 Mucosal transmission

A31 Vertical transmission

A32 Blood-borne transmission

A33 Founder viruses and transmission bottleneck

A34 Immune responses during acute HIV infection

#### Novel treatment and prevention strategies

A35 Preclinical drug development (including prophylactic drug and microbicide development)

A36 RNA/DNA vaccines

A37 Immunotherapy (including broadly neutralizing antibodies)

#### Novel treatment and prevention strategies

A35 Preclinical drug development (including prophylactic drug and microbicide development)

A36 RNA/DNA vaccines

A37 Immunotherapy (including broadly neutralizing antibodies)

#### Vaccine development

A38 Cell-based preventative vaccines

A39 Adjuvants

A40 Novel vectors and strategies

A41 Antibodies

A42 Correlates of immune protection

#### Co-infections and co-morbidities

A43 HIV-2

A44 Co-infection: TB and other mycobacteria

A45 Co-infection: Viral hepatitis

A46 Co-infection: STIs, including HPV

A47 Co-infection: Other

A48 Co-morbidities: Non-communicable diseases

#### Diagnostic tools for immunological and virological monitoring of HIV infection

A49 Novel assays to measure immune responses

A50 Novel approaches to assess viral load, ARV resistance and tropism

#### Novel animal models

A51 Novel animal models to study pathogenesis (transmission disease progression, spontaneous control)

---

A52 Novel animal models to test interventions (vaccines, cure, antiretrovirals)

---

### Pharmacology of antiretrovirals

A53 In vitro activity

---

A54 Tissue penetration

---

A55 Pharmacokinetic and pharmacodynamics

---